Ischemic complications after percutaneous transluminal coronary angioplasty

American Journal of Medicine

Volumn 108, Issue 4, 2000, Pages 309-316

  Bates, Eric R ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; EPTIFIBATIDE; TICLOPIDINE; TIROFIBAN;

BALLOON; HEART INFARCTION; HUMAN; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; FIBRINOLYTIC AGENTS; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; STENTS;

EID: 0033965835     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(99)00464-7     Document Type: Review

References (65)

1. Ellis SG, Omoigui N, Bittl JA, et al. Analysis and comparison of operator-specific outcomes in interventional cardiology: from a multicenter database of 4860 quality-controlled procedures. Circulation. 1996;93:431-439.
2. Bittl JA. Advances in coronary angioplasty. NEJM. 1996;335:1290-1302.
3. de Feyter PJ, de Jaegere PPT, Murphy ES, Serruys PW. Abrupt coronary artery occlusion during percutaneous transluminal coronary angioplasty. Am Heart J. 1992;123:1633-1642.
4. Bittl JA, Ahmed WH. Relation between abrupt vessel closure and the anticoagulant response to heparin or bivalirudin during coronary angioplasty. Am J Cardiol. 1998;82:50P-56P.
5. The IMPACT-II Investigators. Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet. 1997;349:1422-1428.
6. Haase KK, Mahrholdt H, Schroder S, et al. Frequency and efficacy of glycoprotein IIb/IIIa therapy for treatment of threatened or acute vessel closure in 1332 patients undergoing percutaneous transluminal coronary angioplasty. Am Heart J. 1999;137:234-240.
7. Budde T, Haude M, Hopp HW, et al. A prognostic computer model to individually predict postprocedural complications in interventional cardiology: the INTERVENT Project. Eur Heart J. 1999;20: 354-363.
8. de Feyter PJ, Ruygrok PN. Coronary intervention: risk stratification and management of abrupt coronary occlusion. Eur Heart J. 1995; 16(suppl L):L97-L103.
9. Califf RM, Abdelmeguid AE, Kuntz RE, et al. Myonecrosis after revascularization procedures. J Am Coll Cardiol. 1998;31:241-251.
10. Lincoff AM, Popma JJ, Ellis SG, et al. Abrupt vessel closure complicating coronary angioplasty: clinical, angiographic and therapeutic profile. J Am Coll Cardiol. 1992;19:926-935.
11. White CJ, Ramee SR, Collins TJ, et al. Coronary thrombi increase PTCA risk. Angioscopy as a clinical tool. Circulation. 1996;93:253-258.
12. Toschi V, Gallo R, Lettino M, et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation. 1997;95:594-599.
13. Ohman EM, Harrington RA, Lincoff AM, et al. Early clinical experience with integrelin, an inhibitor of the platelet glycoprotein IIb/ IIIa receptor. Eur Heart J. 1995;16(suppl L):50-55.
14. Topol EJ, Serruys PW. Frontiers in interventional cardiology. Circulation. 1998;98:1802-1820.
15. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. NEJM. 1994;331:489-495.
16. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. NEJM. 1994;331:496-501.
17. Colombo A, Hall P, Nakamura S, et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation. 1995;91:1676-1688.
18. Serruys PW, van Hout B, Bonnier H, et al. Randomized comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II). Lancet. 1998;352:673-681.
19. Williams DO, Braunwald E, Thompson B, et al. Results of percutaneous transluminal coronary angioplasty in unstable angina and non-Q-wave myocardial infarction. Observations from the TIMI IIIB Trial. Circulation. 1996;94:2749-2755.
20. Ambrose JA, Almeida OD, Sharma SK, et al. Adjunctive thrombolytic therapy during angioplasty for ischemic rest angina. Results of the TAUSA Trial. Circulation. 1994;90:69-77.
21. Hartmann JR, McKeever LS, O'Neill WW, et al. Recanalization of chronically occluded aortocoronary saphenous vein bypass grafts with long-term, low dose direct infusion of urokinase (ROBUST): a serial trial. J Am Coll Cardiol. 1996;27:60-66.
22. Glazier JJ, Kiernan FJ, Bauer HH, et al. Treatment of thrombotic saphenous vein bypass grafts using local urokinase infusion therapy with the Dispatch catheter. Cathet Cardiovasc Diagn. 1997;41:261-267.
23. McGarry TF Jr, Gottlieb RS, Morganroth J, et al. The relationship of anticoagulation level and complications after successful percutaneous transluminal coronary angioplasty. Am Heart J. 1992;123: 1445-1451.
24. Neuhaus KL, Zeymer U. Prevention and management of thrombotic complications during coronary interventions. Combination therapy with antithrombins, antiplatelets, and/or thrombolytics: risks and benefits. Eur Heart J. 1995;16 (suppl L):63-67.
25. Laskey MAL, Deutsch E, Barnathan E, Laskey WK. Influence of heparin therapy on percutaneous transluminal coronary angioplasty outcome in unstable angina pectoris. Am J Cardiol. 1990;65: 1425-1429.
26. Weitz JI, Hudoba M, Massel D, et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 1990;86:385-391.
27. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. NEJM. 1995;332:1330-1335.
28. Serruys PW, Herrman J-PR, Simon R, et al. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. NEJM. 1995;333:757-763.
29. Bittl JA, Strony J, Brinker JA, et al. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. NEJM. 1995;333:764-769.
30. Klein W, Buchwald A, Hillis SE, et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease: Fragmin in Unstable Coronary Artery Disease Study (FRIC). Circulation. 1997;96:61-68.
31. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. NEJM. 1997;337:447-452.
32. Glick A, Kornowski R, Michowich Y, et al. Reduction of reinfarction and angina with use of low-molecular-weight heparin therapy after streptokinase (and heparin) in acute myocardial infarction. Am J Cardiol. 1996;77:1145-1148.
33. Karsch KR, Preisack MB, Baildon R, et al. Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty: results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). J Am Coll Cardiol. 1996;28:1437-1443.
34. Cairns JA, Gill J, Morton B, et al. Fish oils and low-molecular-weight heparin for the reduction of restenosis after percutaneous transluminal coronary angioplasty. The EMPAR study. Circulation. 1996;94:1553-1560.
35. Karrillon GJ, Morice MC, Benveniste E, et al. Intracoronary stent implantation without ultrasound guidance and with replacement of conventional anticoagulation by antiplatelet therapy: 30-day clinical outcome of the French Multicenter Registry. Circulation. 1996;94:1519-1527.
36. Gallisti S, Muntean W, Leis HJ. Effects of heparin and hirudin on thrombin generation and platelet aggregation after intrinsic activation of platelet rich plasma. Thromb Haemost. 1995;74:1163-1168.
37. Nilsen DW, Goransson L, Larsen AI, et al. Systemic thrombin generation and activity resistant to low molecular weight heparin administered prior to streptokinase in patients with acute myocardial infarction. Thromb Haemost. 1997;77:57-61.
38. Schwartz L, Bourassa MG, Lespérance J, et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. NEJM. 1988;318:1714-1719.
39. White CW, Chaitman B, Knudson ML, Chisholm RJ. Antiplatelet agents are effective in reducing the acute ischemic complications of angioplasty but do not prevent restenosis: results from the ticlopidine trial. Coron Art Dis. 1991;2:757-767.
40. Lembo NJ, Black AJ, Roubin GS, et al. Effect of pretreatment with aspirin versus aspirin plus dipyridamole on frequency and type of acute complications of percutaneous transluminal coronary angioplasty. Am J Cardiol. 1990;65:422-426.
41. Hall P, Nakamura S, Maiello L, et al. A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. Circulation. 1996;93:215-222.
42. Schömig A, Neumann F-J, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. NEJM. 1996;334:1084-1089.
43. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic drug regimens after coronary artery stenting. Stent Anticoagulation Restenosis Study Investigators. NEJM. 1998;339; 1665-1671.
44. Bertrand ME, Legrand V, Boland J, et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (FANTASTIC) study. Circulation. 1998;98:1597-1603.
45. Urban P, Maycaya C, Rupprecht HJ, et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the Multicenter Aspirin and Ticlopidine Trial after Intracoronary Stenting (MATTIS). Circulation. 1998;98:2126-2132.
46. Morris DC. Results from late-breaking clinical trials sessions at ACCIS '99 and ACC '99. J Am Coll Cardiol. 1999;34:1-8.
47. Coukell AJ, Markham A. Clopidogrel. Drugs. 1997;54:745-750.
48. Berger PB. Aspirin, ticlopidine, and clopidogrel in and out of the catheterization laboratory. J Invas Cardiol. 1999;11(suppl A):20A-29A.
49. Tcheng JE, Ellis SG, George BS, et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation. 1994;90:1757-1764.
50. Coller BS, Scudder LE, Beer J, et al. Monoclonal antibodies to platelet glycoprotein IIb/IIIa as antithrombotic agents. Ann N Y Acad Sci. 1991;614:193-213.
51. Simon DI, Xu H, Ortlepp S, et al. 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. Arterioscler Thromb Vasc Biol. 1997;17:528-535.
52. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. NEJM. 1994;330:956-961.
53. Aguirre FV, Topol EJ, Leimberger J, et al. Incidence and clinical outcome of abrupt vessel closure among patients receiving abciximab during high-risk percutaneous coronary intervention: EPIC trial results. J Am Coll Cardiol. 1997;29:394A. Abstract.
54. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. NEJM. 1997;336:1689-1696.
55. The CAPTURE Investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet. 1997;349:1429-1435.
56. Harrington RA, Kleiman NS, Kottke-Marchant K, et al. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol. 1995;76:1222-1227.
57. Tcheng JE. Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. Am J Cardiol. 1996;78(suppl 3A):35-40.
58. Scarborough RM, Naughton MA, Teng W, et al. Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa. J Biol Chem. 1993;268:1066-1073.
59. 2+ on GP IIb-IIIa interactions with Integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation. 1997;96:1488-1494.
60. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. NEJM. 1998;339:436-443.
61. The RESTORE Investigators. Effects of platelet glycoprotein IIb/ IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation. 1997;96:1445-1453.
62. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. NEJM. 1998;338:1488-1497.
63. Kereiakes DJ, Lincoff AM, Miller DP, et al. Abciximab therapy and unplanned coronary stent deployment. Favorable effects on stent use, clinical outcomes, and bleeding complications. Circulation. 1998;97:857-864.
64. The EPISTENT Investigators. Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet. 1998;352:87-92.
65. Lincoff AM, Califf RM, Moliterno DJ, et al. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. NEJM. 1999;341:319-27.